As drug discovery moves beyond traditional small-molecule inhibitors, analytical scientists are being asked to characterize increasingly complex molecules. Proteolysis-targeting chimeras (PROTACs) are one example. PROTACs combine two binding elements with a linker to selectively target proteins for degradation. Their larger size, flexibility, and multiple functional groups can create new analytical considerations compared to more conventional…